CD_(44)v_9基因在恶性卵巢肿瘤中的表达及其临床意义

Expression of CD_(44) v_( 9) Gene and Its Clinical Significance in Malignant Ovarian Tumor

目的：探讨恶性卵巢肿瘤组织中ＣＤ４４ｖ９ 基因表达及其临床意义。方法：用ＲＴ－ ＰＣＲ 方法检测了４１ 例恶性卵巢肿瘤、２０ 例良性卵巢肿瘤和２１ 例正常卵巢组织中ＣＤ４４ｖ９ 基因表达情况并分析相关的临床病理因素。结果：１）ＣＤ４４ｖ９ 基因表达阳性率恶性组明显高于良性组和正常组，良性组高于正常组；２）ＣＤ４４ｖ９ 基因表达在有转移者阳性率显著高于无转移者，转移灶阳性率高于原发灶；３）ＣＤ４４ｖ９ 阳性表达率与临床期别有一定关系，但与病理类型、组织学级别、预后无关。结论：１）ＣＤ４４ｖ９ 基因与肿瘤的发生、发展相关；２）ＣＤ４４ｖ９ 与卵巢恶性肿瘤的浸润和转移相关，可以作为预测肿瘤转移潜能指标。

Purpose: To detect the expression of CD 44 v 9 gene in ovarian cancer and to evaluate its clinical significance in malignant ovarian tumors. Methods: The reverse transcription polymerase chain reaction (RT-PCR) was used to determine the CD 44 v 9 mRNAs expression in biopsy samples of 41 malignant ovarian tumors, 20 benign ovarian tumors and 21 normal controls. Results:1) the positive expression rates of CD 44 v 9 mRNA in malignant tumors were significantly higher than those in benign tumors and controls, and the expression was higher in benign diseases than that in controls. 2) the positive expression rate of CD 44 v 9 in metastatic focus was markedly higher than that in primary focus and the positive rate in primary focus with metastasis was higher than that without metastasis. 3) No significant correlation was observed between the positive expression rate of CD 44 v 9 and the pathological type or histologic grade of the tumor. Conclusion: 1) CD 44 v 9 correlates with the carcinogenesis and progress of tumor. 2) The expression of CD 44 v 9 correlates well with the metastasis of malignant ovarian tumor, as a result, it may be used predicting occurrance of metastasis of ovarian cancer.